CG
Chandrakant Gawli
Also known as: Chandrakant Suryakant Gawli
R C Patel Institute of Pharamceutical Education and Reserach, R C Patel Institute of Pharmaceutical Education and Research
0000-0002-6917-4610
Employment
-
R C Patel Institute of Pharamceutical Education and Reserach Project Research Scientist
Education
-
R C Patel Institute of Pharmaceutical Education and Research M. Pharmacy2021 - 2023
Projects & Funding
Projects & funding information is unavailable.
Publications (16)
- Optimizing the Cardiotoxicity Profile of Osimertinib via Scaffold Hopping: An Integrated Cheminformatics and Molecular Modeling Approach Save
- A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer Save
- Flavokawain A: A Natural MAO-A Inhibitor With Therapeutic Promise for Depression Save
- Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer Save
- NUTRACEUTICAL FRUITS USED IN INFLAMMATORY BOWEL DISEASE Save
- Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis Save
- Quinazoline-based fourth-generation EGFR tyrosine kinase inhibitors to overcome C797S-mediated resistance in non-small cell lung Cancer (NSCLC) Save
- Repurposing clonixin and flunixin as anti-fibrotic candidates: Computational and preclinical evaluation in bleomycin-induced pulmonary fibrosis in rats Save
- Synthesis, impurity profiling, simultaneous NP-HPTLC method development, molecular modelling study and EGFR tyrosine kinase inhibitory profile: An integrated approach to characterize desethynyl erlotinib process impurity Save
- Neuronal Regulation of Thermogenesis and Energy Expenditure in Metabolic Syndrome Save